Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Radiol. bras ; 55(2): 78-83, mar.-abr. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1365299

ABSTRACT

Abstract Objective: To describe the radiological findings in pediatric patients with hematological or oncological diseases who also have an invasive fungal infection (IFI). Materials and Methods: This was a retrospective study of all patients with IFI admitted to a pediatric hematology and oncology hospital in Brazil between 2008 and 2014. Clinical and demographic data were collected. Chest computed tomography (CT) scans of the patients were reviewed by two independent radiologists. Results: We evaluated the chest CT scans of 40 pediatric patients diagnosed with an IFI. Twenty-seven patients (67.5%) had nodules with the halo sign, seven (17.5%) had cavities, two (5.0%) had nodules without the halo sign, and seven (17.5%) had consolidation. The patients with the halo sign and cavities were older (123 vs. 77 months of age; p = 0.03) and had less severe disease (34% vs. 73%; p = 0.04). Ten patients had a proven IFI: with Aspergillus sp. (n = 4); with Candida sp. (n = 5); or with Fusarium sp. (n = 1). Conclusion: A diagnosis of IFI should be considered in children and adolescents with risk factors and abnormal CT scans, even if the imaging findings are nonspecific.


Resumo Objetivo: O objetivo deste estudo é descrever os achados radiológicos de infecções fúngicas invasivas em crianças com doenças onco-hematológicas em um único centro, de acordo com a classificação antiga e a atual de imagens típicas e atípicas. Materiais e Métodos: Foram revisados os prontuários de todos os pacientes com infecção fúngica invasiva que foram internados em um hospital pediátrico de oncologia e hematologia de 2008 a 2014. Foram coletados dados clínicos e demográficos. As tomografias de tórax dos pacientes foram laudadas por dois radiologistas independentes. Resultados: Foram identificados 40 pacientes com infecção fúngica invasiva que realizaram tomografias de tórax. Vinte e sete pacientes apresentaram nódulos com sinal do halo (67,5%), sete tiveram cavitações (17,5%), dois tiveram nódulos sem halo (5,0%) e sete apresentaram consolidações (17,5%). Os pacientes que apresentavam achados de nódulos com sinal do halo e cavitações eram mais velhos (123 versus 77 meses; p = 0,03) e tinham menos sinais de doença grave (34% versus 73%; p = 0,04) do que os outros pacientes. Dez crianças apresentaram infecção confirmada (Aspergillus sp., n = 4; Candida sp., n = 5; Fusarium sp., n = 1). Conclusão: O diagnóstico de infecção fúngica invasiva deve ser considerado em crianças com fatores de risco e tomografias de tórax alteradas, mesmo que os achados das imagens sejam inespecíficos.

2.
Article in English | LILACS-Express | LILACS | ID: biblio-1376305

ABSTRACT

ABSTRACT This study aims to assess COVID-19 and other respiratory viruses in pediatric patients. Between April 17 and September 30, 2020, we collected 1,566 respiratory samples from 1,044 symptomatic patients who were younger than 18 years old to assess SARS-CoV-2 infection. Of these, 919 were analyzed for other respiratory pathogens (ORP). Patients with laboratory-confirmed COVID-19 or ORP were included. We evaluated 76 pediatric COVID-19 infections and 157 other respiratory virus infections. Rhinovirus occurred in 132/157 (84%). COVID-19 patients who were significantly older, had more fevers, headaches and pneumonia than those with ORP. The median white blood cell count was lower in patients with SARS-CoV-2 than in those with ORP (6,470 versus 8,170; p=0.02). COVID-19 patients had significantly worse symptoms than those with ORP.

3.
Article in English | LILACS-Express | LILACS | ID: biblio-1387338

ABSTRACT

ABSTRACT This study assessed the technical performance of a rapid lateral flow immunochromatographic assay (LFIA) for the detection of anti-SARS-CoV-2 IgG and compared LFIA results with chemiluminescent immunoassay (CLIA) results and an in-house enzyme immunoassay (EIA). To this end, a total of 216 whole blood or serum samples from three groups were analyzed: the first group was composed of 68 true negative cases corresponding to blood bank donors, healthy young volunteers, and eight pediatric patients diagnosed with other coronavirus infections. The serum samples from these participants were obtained and stored in a pre-COVID-19 period, thus they were not expected to have COVID-19. In the second group of true positive cases, we chose to replace natural cases of COVID-19 by 96 participants who were expected to have produced anti-SARS-CoV-2 IgG antibodies 30-60 days after the vaccine booster dose. The serum samples were collected on the same day that LFIA were tested either by EIA or CLIA. The third study group was composed of 52 participants (12 adults and 40 children) who did or did not have anti-SARS-CoV-2 IgG antibodies due to specific clinical scenarios. The 12 adults had been vaccinated more than seven months before LFIA testing, and the 40 children had non-severe COVID-19 diagnosed using RT-PCR during the acute phase of infection. They were referred for outpatient follow-up and during this period the serum samples were collected and tested by CLIA and LFIA. All tests were performed by the same healthcare operator and there was no variation of LFIA results when tests were performed on finger prick whole blood or serum samples, so that results were grouped for analysis. LFIA's sensitivity in detecting anti-SARS-CoV-2 IgG antibodies was 90%, specificity 97.6%, efficiency 93%, PPV 98.3%, NPV 86.6%, and likelihood ratio for a positive or a negative result were 37.5 and 0.01 respectively. There was a good agreement (Kappa index of 0.677) between LFIA results and serological (EIA or CLIA) results. In conclusion, LFIA analyzed in this study showed a good technical performance and agreement with reference serological assays (EIA or CLIA), therefore it can be recommended for use in the outpatient follow-up of non-severe cases of COVID-19 and to assess anti-SARS-CoV-2 IgG antibody production induced by vaccination and the antibodies decrease over time. However, LFIAs should be confirmed by using reference serological assays whenever possible.

4.
Marques, Heloisa Helena de Sousa; Pereira, Maria Fernanda Badue; Santos, Angélica Carreira dos; Fink, Thais Toledo; Paula, Camila Sanson Yoshino de; Litvinov, Nadia; Schvartsman, Claudio; Delgado, Artur Figueiredo; Gibelli, Maria Augusta Bento Cicaroni; Carvalho, Werther Brunow de; Odone Filho, Vicente; Tannuri, Uenis; Carneiro-Sampaio, Magda; Grisi, Sandra; Duarte, Alberto José da Silva; Antonangelo, Leila; Francisco, Rossana Pucineli Vieira; Okay, Thelma Suely; Batisttella, Linamara Rizzo; Carvalho, Carlos Roberto Ribeiro de; Brentani, Alexandra Valéria Maria; Silva, Clovis Artur; Eisencraft, Adriana Pasmanik; Rossi Junior, Alfio; Fante, Alice Lima; Cora, Aline Pivetta; Reis, Amelia Gorete A. de Costa; Ferrer, Ana Paula Scoleze; Andrade, Anarella Penha Meirelles de; Watanabe, Andreia; Gonçalves, Angelina Maria Freire; Waetge, Aurora Rosaria Pagliara; Silva, Camila Altenfelder; Ceneviva, Carina; Lazari, Carolina dos Santos; Abellan, Deipara Monteiro; Santos, Emilly Henrique dos; Sabino, Ester Cerdeira; Bianchini, Fabíola Roberta Marim; Alcantara, Flávio Ferraz de Paes; Ramos, Gabriel Frizzo; Leal, Gabriela Nunes; Rodriguez, Isadora Souza; Pinho, João Renato Rebello; Carneiro, Jorge David Avaizoglou; Paz, Jose Albino; Ferreira, Juliana Carvalho; Ferranti, Juliana Ferreira; Ferreira, Juliana de Oliveira Achili; Framil, Juliana Valéria de Souza; Silva, Katia Regina da; Kanunfre, Kelly Aparecida; Bastos, Karina Lucio de Medeiros; Galleti, Karine Vusberg; Cristofani, Lilian Maria; Suzuki, Lisa; Campos, Lucia Maria Arruda; Perondi, Maria Beatriz de Moliterno; Diniz, Maria de Fatima Rodrigues; Fonseca, Maria Fernanda Mota; Cordon, Mariana Nutti de Almeida; Pissolato, Mariana; Peres, Marina Silva; Garanito, Marlene Pereira; Imamura, Marta; Dorna, Mayra de Barros; Luglio, Michele; Rocha, Mussya Cisotto; Aikawa, Nadia Emi; Degaspare, Natalia Viu; Sakita, Neusa Keico; Udsen, Nicole Lee; Scudeller, Paula Gobi; Gaiolla, Paula Vieira de Vincenzi; Severini, Rafael da Silva Giannasi; Rodrigues, Regina Maria; Toma, Ricardo Katsuya; Paula, Ricardo Iunis Citrangulo de; Palmeira, Patricia; Forsait, Silvana; Farhat, Sylvia Costa Lima; Sakano, Tânia Miyuki Shimoda; Koch, Vera Hermina Kalika; Cobello Junior, Vilson; HC-FMUSP Pediatric COVID Study Group.
Clinics ; 76: e3488, 2021. tab, graf
Article in English | LILACS | ID: biblio-1350619

ABSTRACT

OBJECTIVES: To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). METHODS: This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. RESULTS: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). CONCLUSIONS: Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19.


Subject(s)
Humans , Infant, Newborn , Child , Adolescent , COVID-19/complications , Cross-Sectional Studies , Cohort Studies , Systemic Inflammatory Response Syndrome , Tertiary Care Centers , SARS-CoV-2
5.
Clinics ; 75: e2209, 2020. tab
Article in English | LILACS | ID: biblio-1133484

ABSTRACT

OBJECTIVES: To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C). METHODS: This cross-sectional study included 471 samples collected from 371 patients (age<18 years) suspected of having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study group comprised 66/371 (18%) laboratory-confirmed pediatric COVID-19 patients: 61 (92.5%) patients tested positive on real-time reverse transcription-polymerase chain reaction tests for SARS-CoV-2, and 5 (7.5%) patients tested positive on serological tests. MIS-C was diagnosed according to the criteria of the Center for Disease Control. RESULTS: MIS-C was diagnosed in 6/66 (9%) patients. The frequencies of diarrhea, vomiting, and/or abdominal pain (67% vs. 22%, p=0.034); pediatric SARS (67% vs. 13%, p=0.008); hypoxemia (83% vs. 23%, p=0.006); and arterial hypotension (50% vs. 3%, p=0.004) were significantly higher in patients with MIS-C than in those without MIS-C. The frequencies of C-reactive protein levels >50 mg/L (83% vs. 25%, p=0.008) and D-dimer levels >1000 ng/mL (100% vs. 40%, p=0.007) and the median D-dimer, troponin T, and ferritin levels (p<0.05) were significantly higher in patients with MIS-C. The frequencies of pediatric intensive care unit admission (100% vs. 60%, p=0.003), mechanical ventilation (83% vs. 7%, p<0.001), vasoactive agent use (83% vs. 3%, p<0.001), shock (83% vs. 5%, p<0.001), cardiac abnormalities (100% vs. 2%, p<0.001), and death (67% vs. 3%, p<0.001) were also significantly higher in patients with MIS-C. Similarly, the frequencies of oxygen therapy (100% vs. 33%, p=0.003), intravenous immunoglobulin therapy (67% vs. 2%, p<0.001), aspirin therapy (50% vs. 0%, p<0.001), and current acute renal replacement therapy (50% vs. 2%, p=0.002) were also significantly higher in patients with MIS-C. Logistic regression analysis showed that the presence of MIS-C was significantly associated with gastrointestinal manifestations [odds ratio (OR)=10.98; 95%CI (95% confidence interval)=1.20-100.86; p=0.034] and hypoxemia [OR=16.85; 95%CI=1.34-211.80; p=0.029]. Further univariate analysis showed a positive association between MIS-C and death [OR=58.00; 95%CI=6.39-526.79; p<0.0001]. CONCLUSIONS: Pediatric patients with laboratory-confirmed COVID-19 with MIS-C had a severe clinical spectrum with a high mortality rate. Our study emphasizes the importance of investigating MIS-C in pediatric patients with COVID-19 presenting with gastrointestinal involvement and hypoxemia.


Subject(s)
Humans , Male , Child , Pneumonia, Viral/complications , Pneumonia, Viral/mortality , Coronavirus Infections/complications , Coronavirus Infections/mortality , Coronavirus , Pandemics , Respiration, Artificial , Vomiting/etiology , Abdominal Pain/etiology , Cross-Sectional Studies , Immunoglobulins, Intravenous/therapeutic use , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Systemic Inflammatory Response Syndrome/epidemiology , Diarrhea/etiology , Fever/etiology , Betacoronavirus , SARS-CoV-2 , COVID-19 , Glucocorticoids/therapeutic use , Mucocutaneous Lymph Node Syndrome/therapy , Mucocutaneous Lymph Node Syndrome/epidemiology , Mucocutaneous Lymph Node Syndrome/virology
6.
Rev. paul. pediatr ; 33(3): 326-331, jul.-set. 2015. tab
Article in Portuguese | LILACS | ID: lil-761143

ABSTRACT

Objetivo:Verificar a prevalência de sedentarismo entre adolescentes com HIV/Aids e seus fatores associados.Métodos:Foram entrevistados 91 adolescentes de 10 a 19 anos, com HIV/Aids, em acompanhamento em uma unidade de infectologia universitária. Foram coletados dados antropométricos (peso, altura e circunferência da cintura) em duplicata, informações clínicas foram obtidas nos prontuários médicos e a prática de atividade física habitual foi medida por meio do questionário proposto por Florindo et al. O ponto de corte para sedentarismo foi de 300 minutos/semana.Resultados:As prevalências de altura inadequada para idade, desnutrição e sobrepeso/obesidade foram de 15,4%, 9,9% e 12,1%, respectivamente. As atividades físicas mais citadas foram: futebol (44,4%), voleibol (14,4%) e andar de bicicleta (7,8%). Os tempos medianos dispendidos com a prática de atividade física e caminhando/andando de bicicleta até a escola foram de 141 minutos e 39 minutos, respectivamente. A maioria dos adolescentes (71,4%) era sedentária, proporção maior entre as meninas (p=0,046).Conclusões:Foi observada alta prevalência de sedentarismo entre adolescentes com HIV/Aids, prevalência essa semelhante àquela observada na população geral. Promover a prática de atividade física entre adolescentes - especialmente entre meninas - com HIV/Aids, assim como monitorá-la, deve fazer parte da rotina de acompanhamento desses pacientes.


Objective:To assess the prevalence of physical inactivity among adolescents with HIV/AIDS, as well as associated factors.Methods:Ninety-one adolescents (from 10 to 19 years old) with HIV/AIDS who are patients at a university follow-up service were interviewed. Anthropometric data (weight, height, and waist circumference) were measured twice; clinical information was obtained from medical records, and habitual physical activity was assessed by a questionnaire proposed by Florindo et al. The cutoff point for sedentariness was 300 minutes/week.Results:The prevalence of inadequate height for age, malnutrition, and overweight/obesity was 15.4%, 9.9% and 12.1%, respectively. The most common physical activities were soccer (44.4%), volleyball (14.4%) and cycling (7.8%). The median times spent with physical activity and walking/bicycling to school were 141 min and 39 min, respectively. Most adolescents (71.4%) were sedentary and this proportion was higher among girls (p=0.046).Conclusions:A high prevalence of physical inactivity among adolescents with HIV/AIDS was observed, similar to the general population. Promoting physical activity among adolescents, especially among girls with HIV/AIDS, as well as monitoring it should be part of the follow-up routine of these patients.


Subject(s)
Humans , Male , Female , Adolescent , Motor Activity , Sedentary Behavior , Acquired Immunodeficiency Syndrome
7.
Clinics ; 70(7): 515-523, 2015. tab
Article in English | LILACS | ID: lil-752395

ABSTRACT

Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia. .


Subject(s)
Humans , Cytomegalovirus Infections/etiology , Postoperative Complications , Transplant Recipients , Cytomegalovirus , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/therapy , Graft Rejection/etiology , Postoperative Complications/diagnosis , Postoperative Complications/therapy
8.
Rev. Soc. Bras. Med. Trop ; 47(5): 543-546, Sep-Oct/2014.
Article in English | LILACS | ID: lil-728896

ABSTRACT

Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) is one of the most serious complications associated with solid organ and hematopoietic stem cell transplantation. PTLD is most frequently seen with primary EBV infection post-transplant, a common scenario for pediatric solid organ recipients. Risk factors for infection or reactivation of EBV following solid organ transplant are stronger immunosuppressive therapy regimens, and being seronegative for receptor. For hematopoietic stem cell transplantation, the risk factors relate to the type of transplant, human leukocyte antigen disparity, the use of stronger immunosuppressants, T-cell depletion, and severe graft-versus-host disease. Mortality is high, and most frequent in patients who develop PTLD in the first six months post-transplant. The primary goal of this article is to provide an overview of the clinical manifestations, diagnosis, accepted therapies, and management of EBV infection in transplant recipients, and to suggest that the adoption of monitoring protocols could contribute to a reduction in related complications.


Subject(s)
Humans , Epstein-Barr Virus Infections , Hematopoietic Stem Cell Transplantation/adverse effects , Lymphoproliferative Disorders/virology , Organ Transplantation/adverse effects , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/prevention & control , Epstein-Barr Virus Infections/therapy , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Risk Factors
9.
Cad. saúde pública ; 29(11): 2197-2207, Nov. 2013. ilus, graf, tab
Article in English | LILACS | ID: lil-690755

ABSTRACT

In clinical practice, recurrence of thrush is common in children living with HIV/AIDS. The aim of this study was to determine the factors associated with time spent free of oral candidiasis using survival analysis for recurrent events. A retrospective cohort study was carried out with 287 children treated between 1985 and 2009 at a reference center in the city of São Paulo, Brazil. The Prentice, Williams and Peterson model for recurrent events was used for the investigation of factors associated with the time free of oral candidiasis. The following factors were associated with the time patients were free of oral candidiasis: moderate immunodepression (HR = 2.5; p = 0.005), severe immunodepression (HR = 3.5; p < 0.001), anemia (HR = 3.3; p < 0.001), malnutrition (HR = 2.6; p = 0.004), hospitalization (HR = 2.2; p < 0.001), monotherapy (HR = 0.5; p = 0.006), dual therapy (HR = 0.3; p < 0.001) and triple therapy/highly active antiretroviral therapy (HR = 0.1; p < 0.001). The method analyzed in the present study proved useful for the investigation of recurrent events in patients living with HIV/AIDS.


A recorrência da candidíase oral em crianças vivendo com HIV/AIDS é um acontecimento muito comum na prática clínica. O objetivo foi verificar os fatores associados ao tempo livre de candidíase oral, utilizando técnica de análise de sobrevida para eventos recorrentes. Estudo de coorte retrospectivo com 287 crianças, atendidas entre 1985 e 2009, em um serviço de saúde de São Paulo, Brasil. Foi utilizado o modelo marginal para eventos recorrentes de Prentice, Williams e Peterson para investigação dos fatores associados ao tempo livre de candidíase oral. Imunodepressão moderada (HR = 2,5; p = 0,005) ou grave (HR = 3,5; p < 0,001), anemia (HR = 3,3; p < 0,001), desnutrição (HR = 2,6; p = 0,004) e internação (HR = 2,2; p < 0,001), monoterapia (HR = 0,5; p = 0,006), terapia dupla (HR = 0,3; p < 0,001) e terapia tripla/HAART (HR = 0,1; p < 0,001) foram associados ao tempo livre de candidíase oral. A metodologia apresentada neste artigo pode ser bastante útil em pesquisas na área de HIV/AIDS, quando pretende-se estudar eventos com comportamento de recorrência.


La repetición de candidiasis oral en los niños que viven con VIH/SIDA es muy común en la práctica clínica. El objetivo fue verificar los factores asociados al tiempo libre y la candidiasis oral, usando la técnica de análisis de supervivencia para eventos recurrentes. Se realizó un estudio de cohorte retrospectiva con 287 niños que visitaron entre 1985 y 2009 un servicio de salud de São Paulo, Brasil. Se usó el modelo marginal para eventos recurrentes de Prentice, Williams y Peterson, con el fin de investigar los factores asociados. Moderada inmunodepresión (HR = 2,5; p = 0,005) o grave (HR = 3,5; p < 0,001), anemia (HR = 3,3; p < 0,001), desnutrición (HR = 2,6; p = 0,004) y hospitalización (HR = 2,2; p < 0,001), monoterapia (HR = 0,5; p = 0, 006), terapia dual (HR = 0,3; p < 0,001) y triple terapia/TARGA (HR = 0,1; p < 0,001) se asociaron al tiempo libre y la candidiasis oral. La metodología presentada en este artículo puede ser útil para la investigación en el área de VIH/SIDA, cuando se pretenda estudiar el comportamiento de la repetición del evento.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , AIDS-Related Opportunistic Infections/microbiology , AIDS-Related Opportunistic Infections/mortality , Candidiasis, Oral/microbiology , Candidiasis, Oral/mortality , AIDS-Related Opportunistic Infections/drug therapy , Anti-HIV Agents/therapeutic use , Cohort Studies , Candidiasis, Oral/drug therapy , Recurrence , Retrospective Studies , Risk Factors , Time Factors
10.
Cad. saúde pública ; 27(supl.1): s93-s103, 2011. graf, tab
Article in English | LILACS | ID: lil-582635

ABSTRACT

The objective of this study is to characterize survival in children with AIDS diagnosed in Brazil between 1999-2002, compared with the first national study (1983-1998). This national retrospective cohort study examined a representative sample of Brazilian children exposed to HIV from mother-to-child transmission and followed through 2007. The survival probability after 60 months was analyzed by sex, year of birth and death, clinical classification, use of antiretroviral therapy (ART) and prophylaxis for opportunistic diseases. 920 children were included. The survival probability increased: comparing cases diagnosed before 1988 with those diagnosed from 2001-2002 it increased by 3.5-fold (from 25 percent to 86.3 percent). Use of ART, initial clinical classification, and final classification were significant (p < 0.001) predictors of survival. Issues regarding quality of records and care were identified. The results point to the success of the Brazilian policy of providing ART. The improvement of clinical status contributes to quality of life, while indicating challenges, particularly practices to improve long-term care.


Este estudo caracteriza a sobrevida em crianças com AIDS no Brasil entre 1999-2002, contextualizando com o primeiro estudo nacional (1983-1998). Trata-se de coorte histórica, com crianças expostas ao HIV por transmissão vertical e acompanhadas até 2007. A probabilidade de sobrevivência em 60 meses foi analisada segundo sexo, ano de nascimento e de óbito, classificação clínica, uso de terapia antirretroviral (TARV) e de profilaxia para doenças oportunistas. No total, 920 crianças foram incluídas. A probabilidade de sobrevivência foi ampliada 3,5 vezes nos dois períodos avaliados, passando de 25 por cento antes de 1988 para 86,3 por cento no período de 2001-2002. Uso de TARV, classificação clínica inicial e atual/final foram preditores que influíram significativamente (p < 0,001) para a ampliação da sobrevida. Os resultados deste estudo indicam o sucesso da política brasileira para a abordagem das crianças infectadas com HIV. A melhora do estado clínico contribuiu para melhora da qualidade de vida, mas sinaliza-se para a necessidade de incorporação de práticas pautadas na integralidade do cuidado.


Subject(s)
Child , Female , Humans , Male , Acquired Immunodeficiency Syndrome/mortality , Infectious Disease Transmission, Vertical , Acquired Immunodeficiency Syndrome , Acquired Immunodeficiency Syndrome/transmission , Anti-HIV Agents , Cohort Studies , Retrospective Studies , Survival Analysis
11.
Pediatr. mod ; 45(4): 125-138, jul.-ago. 2009. tab
Article in Portuguese | LILACS | ID: lil-524560

ABSTRACT

Os autores atualizam os conhecimentos mais recentes a respeito das protozooses na infância, compreendendo as formas intestinais e aquelas que acometem sangue e tecidos. Em cada caso, o trabalho analisa a importância da infestação, sua conceituação e incidência, epidemiologia e microbiologia, clínica, e diagnóstico clínico, através de exames complementares e tratamento.As infecções parasitárias são ubíquas no mundo e se estima que cerca de um bilhão de pessoas estejam infestadas por helmintos intestinais. Infecções ou infestações parasitárias podem ocorrer em crianças de qualquer idade as pequenas que frequentam creches estão sob risco, por exemplo, de adquirir giardíase, disseminada através das fezes contaminadas. As crianças em idade pré-escolar e escolar precoce podem adquirir enterobíase (oxiuríase), além de escabiose e pediculose, estas últimas adquiridas também por contato íntimo interpessoal. Em todas as idades há risco de giardíase ou criptosporidiose, devido à ingestão de água contaminada em piscinas ou outras atividades recreacionais em lagoas, fontes, lagos, rios e cachoeiras etc.O contato com animais, de estimação ou não, é outra fonte potencial de exposição a parasitas e potenciais causadores de doenças, como Toxoplasma (contato com as fezes de gatos) e Toxocara (excretas de filhotes de cães e gatos). Além dessas circunstâncias, deve-se lembrar que algumas das doenças parasitárias são endêmicas em algumas regiões e viagens podem determinar risco aumentado de exposição e desenvolvimento de doenças.Os parasitas são definidos como micro-organismos uni ou multicelulares. Podem ser didaticamente classificados em dois grupos: parasitas unicelulares ou protozoários (subdivididos em intestinais e de sangue e tecidos) e multicelulares ou helmintos. Neste artigo serão abordadas as infestações por protozoários.

12.
J. pediatr. (Rio J.) ; 84(1): 41-46, Jan.-Feb. 2008. ilus, tab
Article in English, Portuguese | LILACS | ID: lil-476707

ABSTRACT

OBJETIVO: Validar uma escala de auto-eficácia para adesão ao tratamento anti-retroviral em crianças e adolescentes com HIV/AIDS, levando em consideração a perspectiva dos pais/responsáveis, e avaliar a sua reprodutibilidade. MÉTODOS: O estudo foi realizado no Hospital-Dia do Centro de Referência e Treinamento em DST/AIDS de São Paulo. Foram entrevistados os pais/responsáveis de 54 crianças e adolescentes de 6 meses a 20 anos que passaram em consulta de rotina pelo serviço. Os dados de auto-eficácia foram levantados pela escala de auto-eficácia para seguir prescrição anti-retroviral (AE), que foi calculada de duas maneiras: análise fatorial e fórmula já definida. A consistência interna da escala foi verificada pelo coeficiente ade Cronbach. A validade foi avaliada pela comparação das médias dos escores entre grupos de pacientes aderentes e não aderentes ao tratamento anti-retroviral (teste de Mann-Whitney) e cálculo do coeficiente de correlação de Spearman entre os escores e parâmetros clínicos. A reprodutibilidade foi verificada por meio do teste de Wilcoxon, pelo coeficiente de correlação intraclasse (CCI) e pelo gráfico de Bland-Altman. RESULTADOS: A escala de AE apresentou boa consistência interna (a= 0,87) e boa reprodutibilidade (CCI = 0,69 e CCI = 0,75). Quanto à validade, a escala de AE conseguiu discriminar pacientes aderentes e não aderentes ao tratamento anti-retroviral (p = 0,002) e apresentou correlação significativa com a contagem de CD4 (r = 0,28; p = 0,04). CONCLUSÕES: A escala de AE pode ser utilizada para avaliar a adesão à terapia anti-retroviral em crianças e adolescentes com HIV/AIDS, levando em consideração a perspectiva dos pais/cuidadores.


OBJECTIVE: To validate and evaluate the reproducibility of a self-efficacy (SE) scale for adherence to antiretroviral therapy in children and adolescents with HIV/AIDS, taking into account the perspective of parents/guardians. METHODS: The study was carried out at the Hospital-Dia, Centro de Referência e Treinamento em DST/AIDS (CRT/SP), in São Paulo, Brazil. The parents/guardians of 54 children and adolescents aged 6 months to 20 years were interviewed during routine consultations at our service. Data on SE were collected using the Self-Efficacy for Following Anti-Retroviral Prescription Scale, and SE scores were calculated in two different ways: factor analysis and a predefined formula. The scale's internal consistency was verified using Cronbach's acoefficient. Validity was tested by comparing the mean scores of a group of patients who did adhere to antiretroviral treatment with those of a group that did not (Mann-Whitney test) and by calculating the Spearman correlation coefficient for agreement between scores and clinical parameters. Reproducibility was verified using the Wilcoxon test, intraclass correlation coefficients (r icc) and Bland-Altman plots. RESULTS: The SE scale demonstrated good internal consistency (a= 0.87) and good reproducibility (r icc = 0.69 and r icc = 0.75). In terms of validity, the SE scale was capable of differentiating adherent patients from those who did not adhere to their antiretroviral treatment (p = 0.002) and exhibited a significant correlation with CD4 counts (r = 0.28; p = 0.04). CONCLUSIONS: The SE scale can be used to assess adherence to antiretroviral therapy in children and adolescents with HIV/AIDS, taking into account the perspective of parents/carers.


Subject(s)
Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Male , Anti-HIV Agents/therapeutic use , Caregivers , HIV Infections/drug therapy , Parents , Patient Compliance/statistics & numerical data , Surveys and Questionnaires/standards , Reproducibility of Results , Statistics, Nonparametric
13.
Cad. saúde pública ; 23(supl.3): S402-S413, 2007. graf, tab
Article in English | LILACS | ID: lil-466332

ABSTRACT

The objective of this study was to estimate and analyze the costs of treating children with HIV/AIDS at a university hospital in São Paulo, Brazil. The study collected and analyzed data from 291 medical records of children treated at the hospital as of March 2002. The costs of treatment were estimated for each category of patient (exposed and infected) and severity, based on the quantity of inputs and procedures used in treating each child, based on the cost accounting system used at the hospital. The total cost of treatment for children exposed to the HIV was R$ 956.41 and for those infected with HIV R$ 8,092.71 per year. The mean cost of ambulatory care was R$ 6,047.28 for children with severe conditions, R$ 3,714.45 for those with light/moderate conditions, and R$ 948.63 for the exposed. Hospitalized children had annual costs of R$ 19,353.34, R$ 18,823.16, and R$ 871.03, respectively. The medication was a major factor in the cost of treatment. Our estimates are comparable to the findings from other studies, but lower than corresponding findings from the international literature.


O objetivo deste estudo foi estimar e analisar os custos de tratamento da criança com HIV/AIDS em um hospital universitário de São Paulo, Brasil. Foram analisados 291 prontuários de crianças expostas ou infectadas acompanhadas no Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, em março de 2002. O custo foi estimado por categoria de paciente (exposta e infectada) e nível de gravidade (graves e leves/moderados), com base na quantidade de procedimentos e insumos utilizados no tratamento, e valorizado monetariamente por meio do sistema de apuração de custos existente no Instituto da Criança. O custo total estimado de tratamento da criança exposta ao HIV foi de R$ 956,41 e da criança infectada de R$ 8.092,71 por ano. O custo do tratamento ambulatorial foi de R$ 6.047,28, R$ 3.714,45 e R$ 948,63, respectivamente para os pacientes infectados graves, leves/moderados e para as crianças expostas, e o custo médio de internação foi de R$ 19.353,34, R$ 18.823,16 e R$ 871,03, respectivamente. O custo foi fortemente influenciado pelo consumo de medicamentos e comparável aos obtidos pelos demais estudos publicados, embora inferior ao estimado em estudos internacionais.


Subject(s)
Child , Humans , Antiretroviral Therapy, Highly Active/economics , Health Care Costs , HIV Infections/economics , Hospitalization/economics , Acquired Immunodeficiency Syndrome/economics , Ambulatory Care/economics , Brazil , Cost-Benefit Analysis , Hospitals, University/economics , Severity of Illness Index
14.
Cad. saúde pública ; 23(supl.3): S435-S444, 2007. graf, tab
Article in English | LILACS | ID: lil-466335

ABSTRACT

Antiretroviral therapy contributes to decreasing morbidity and mortality, and ultimately to increasing survival. In Brazil, there are regional differences in HIV epidemiology regarding pregnant women and children with HIV/AIDS. This study evaluates survival time after AIDS diagnosis in 914 children infected by mother-to-child transmission, reported between 1983 and 1998 and followed until 2002, in Brazil's five regions. Time between birth and HIV diagnosis decreased over the years, mainly in the South and Southeast Regions. There was a significant improvement in survival; more than 75 percent of cases were still living four years after diagnosis in the 1997-1998 group. This Brazilian study demonstrates that even with regional inequalities in health care infrastructure it is possible for a developing country to establish an effective system of universal and free access to antiretroviral therapy that produces a significant increase in survival for children with AIDS.


A terapia anti-retroviral contribui para a diminuição da morbidade e da mortalidade, com conseqüente aumento da sobrevida. No Brasil, há diferenças regionais relativas à dinâmica da epidemia do HIV e ao seu enfrentamento no grupo das gestantes e das crianças com HIV/AIDS. Este estudo verifica o tempo de sobrevida após o diagnóstico de AIDS em 914 crianças infectadas por transmissão vertical, entre os anos de 1983 e 1998, e acompanhadas até 2002, nas cinco regiões brasileiras. O tempo do nascimento ao diagnóstico de infecção pelo HIV, ao longo dos anos, apresenta uma diminuição, principalmente nos estados das regiões Sul e Sudeste. Houve melhora significativa da sobrevivência, mais de 75 por cento dos casos ainda estavam vivendo quatro anos após o diagnóstico, no grupo de 1997 e 1998. Esta análise brasileira mostra ser possível para um país em desenvolvimento estabelecer um sistema efetivo de acesso gratuito e universal à terapia anti-retroviral, mesmo com dificuldades regionais para a organização de uma infra-estrutura ideal de saúde, tendo como resultado um aumento significativo da sobrevivência.


Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Pregnancy , HIV Infections/transmission , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/mortality , Acquired Immunodeficiency Syndrome/mortality , Brazil/epidemiology , Cohort Studies , Follow-Up Studies , HIV Infections/diagnosis , National Health Programs , Social Justice , Socioeconomic Factors , Survival Analysis
15.
Rev. bras. ginecol. obstet ; 28(7): 424-430, jul. 2006. tab
Article in Portuguese | LILACS | ID: lil-445982

ABSTRACT

A introdução da profilaxia da transmissão vertical do HIV com o uso de drogas anti-retrovirais aliadas a outras medidas resultou na redução de crianças infectadas pelo HIV em nosso meio. Esses medicamentos são de uso recente e não há dados conclusivos para definir a sua segurança durante a gravidez. Esse artigo analisa, através de revisão bibliográfica, os possíveis efeitos dessas drogas sobre o feto, o recém-nascido e durante a infância, incluindo o potencial de teratogenicidade, carcinogênese e sua toxicidade. As descrições incluem a identificação de risco aumentado na criança para toxicidade mitocondrial, alterações neurológicas, hematológicas, hepáticas em crianças expostas ao HIV. Baseados nos conhecimentos atuais, considera-se que o benefício na acentuada redução da transmissão vertical do HIV com o uso de drogas anti-retrovirais ultrapassa os riscos eventuais dos efeitos adversos. Entretanto, até que experiência de longo prazo se acumule, é necessário acompanhamento clínico especializado das crianças expostas. Nessa revisão sugere-se uma rotina de acompanhamento clínico-laboratorial ao longo do primeiro ano de vida e depois anualmente até o final da adolescência.


The implementation of prophylactic antiretroviral drugs and others strategies to prevent vertical HIV transmission in Brazil has reduced the number of newly HIV-infected children. Since these drugs are only recently available for treatment, there is no data of conclusive safety during pregnancy and fetus and newborn. This article reviews the possible effects of these drugs in fetus, newborn and childhood, including teratogenesis, carcinogenesis and toxicity. In the literature there are an increasing description of adverse effects such as mithocondrial toxicity, neurological symptoms, blood and liver toxicity in HIV-exposed not infected children. Antiretroviral treatment recommendations are based on principles that known benefit to the pregnat woman should be mantained unless adverse effects outweight the benefit. A long term follow up of HIV- exposed children is proposed to better understanding of these potential toxicity. In this review the author suggests a practical clinical and laboratory routinary evaluation during the first years of life until adolescence for HIV-exposed not infected children.


Subject(s)
Pregnancy , Infant, Newborn , Infant , Humans , Female , Antiretroviral Therapy, Highly Active , Fetus , HIV Infections , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious
16.
Cad. saúde pública ; 22(3): 619-629, mar. 2006. tab
Article in Portuguese | LILACS | ID: lil-423248

ABSTRACT

O objetivo deste estudo foi identificar aspectos da revelacão do diagnóstico da infeccão pelo HIV a criancas e adolescentes relevantes para a melhoria do cuidado de sua saúde. Trata-se de estudo qualitativo envolvendo entrevistas em profundidade e grupo focal com adolescentes vivendo com HIV/AIDS e seus pais ou cuidadores, em servicos de referência nas cidades de São Paulo e Santos, Brasil. Os resultados apontam como principais razões para a revelacão: má adesão ao tratamento, iminência de início da vida sexual, demanda da crianca ou adolescente e abordagem inadequada de profissional. A revelacão mostrou-se momento crítico, com repercussões sobre projetos e horizontes de vida dos adolescentes. As mais problemáticas foram narradas por adolescentes infectados por via sexual e por uso de drogas. Apesar do impacto negativo inicial, a revelacão repercutiu positivamente sobre os cuidados de saúde, com melhoria do diálogo com cuidadores e servicos. Os adolescentes enfatizaram ainda a necessidade de receber informacões claras e honestas. Conclui-se pela necessidade de otimizar o processo de revelacão, tratando-o como tarefa de longo prazo, negociada ativamente com a família e conduzida por equipes multidisciplinares.


Subject(s)
Humans , Child , Adolescent , Acquired Immunodeficiency Syndrome , Adolescent , Caregivers , HIV Infections/diagnosis , Truth Disclosure , Attitude to Health
17.
Pediatria (Säo Paulo) ; 28(3): 169-174, 2006. tab
Article in Portuguese | LILACS | ID: lil-450852

ABSTRACT

Objetivo: avaliar aspectos diagnósticos e terapêuticos da tuberculose osteoarticular na unidade de infectologiade um hospital universitário durante dez anos. Resultados: no período, des casos foram diagnosticados...


Objetivo: to describe diagnostic and therapeutic approach to skeletal tuberculosis in children admitted at tertiary level hospital. Casuistic and methods: patients with diagnosis of skeletal tuberculosis were selected from a pediatric infectious diseases...


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Tuberculosis, Osteoarticular/diagnosis , Tuberculosis, Osteoarticular/therapy
19.
In. Farhat, Calil Kairalla; Carvalho, Eduardo da Silva; Weckx, Lily Yin; Carvalho, Luiza Helena Falleiros R; Succi, Regina Célia de Menezes. Imunizaçöes: fundamentos e prática. Säo Paulo, Atheneu, 2000. p.261-72.
Monography in Portuguese | LILACS, SES-SP | ID: lil-281280
20.
In. Assumpçäo Junior, Francisco B. Psiquiatria da infância e da adolescência. Säo Paulo, Santos, 1994. p.477-83, tab.
Monography in Portuguese | LILACS | ID: lil-200606
SELECTION OF CITATIONS
SEARCH DETAIL